Table 2. Treatment response according to T790M status.
| Outcome, n (%) | T790M− (n=78) | P | T790M+ (n=42) | P | Unknown (n=50) | P | |||
|---|---|---|---|---|---|---|---|---|---|
| Chemo (n=41) | Chemo + gefitinib (n=37) | Chemo (n=22) | Chemo + gefitinib (n=20) | Chemo (n=28) | Chemo + gefitinib (n=22) | ||||
| DCR | 24 (58.5) | 26 (70.3) | 0.281 | 16 (72.7) | 14 (70.0) | 0.845 | 10 (35.7) | 13 (59.1) | 0.100 |
| ORR | 8 (19.5) | 13 (35.1) | 0.120 | 5 (22.7) | 5 (25.0) | 0.863 | 5 (17.9) | 6 (27.3) | 0.425 |
| PR | 8 (19.5) | 13 (35.1) | – | 5 (22.7) | 5 (25.0) | – | 5 (17.9) | 6 (27.3) | – |
| SD | 16 (39.0) | 13 (35.1) | – | 11 (50.0) | 9 (45.0) | – | 5 (17.9) | 7 (31.8) | – |
| PD | 17 (41.5) | 11 (29.7) | – | 6 (27.3) | 6 (30.0) | – | 18 (64.3) | 9 (40.9) | – |
DCR, disease control rate; ORR, objective response rate; PR, partial response; SD, stable disease; PD, progressive disease; Chemo, chemotherapy; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.